Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBT (2023 - 2025)

Historic EBT for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$30.3 million.

  • Monte Rosa Therapeutics' EBT fell 2719.86% to -$30.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 11844.8%. This contributed to the annual value of -$70.1 million for FY2024, which is 4805.72% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported EBT of -$30.3 million as of Q3 2025, which was down 2719.86% from -$11.1 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year EBT high stood at $47.7 million for Q1 2025, and its period low was -$35.0 million during Q2 2023.
  • In the last 3 years, Monte Rosa Therapeutics' EBT had a median value of -$30.3 million in 2025 and averaged -$18.1 million.
  • The largest annual percentage gain for Monte Rosa Therapeutics' EBT in the last 5 years was 24962.21% (2025), contrasted with its biggest fall of 2719.86% (2025).
  • Monte Rosa Therapeutics' EBT (Quarter) stood at -$33.3 million in 2023, then surged by 146.89% to $15.6 million in 2024, then tumbled by 293.95% to -$30.3 million in 2025.
  • Its last three reported values are -$30.3 million in Q3 2025, -$11.1 million for Q2 2025, and $47.7 million during Q1 2025.